Bortezomib in Rejection of Kidney Transplants

NCT02201576 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Chronic Antibody-mediated Transplant Rejection

Interventions

DRUG: Bortezomib
DRUG: Plasma exchanges and intravenous immunoglobulins

Sponsor

Assistance Publique - Hôpitaux de Paris

Collaborators

[object Object]
[object Object]